Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
Date:2/28/2013

Randomized, Controlled Trials", Chey, W., et al. 
  • Date: May 21, 2013, 8:15 a.m. Eastern Time
  • Research Forum: New Pharmacological Treatments for Motility Disorders
  • 4th International Congress on Neuropathic Pain, Toronto, Canada:

  • Poster A-484-0002-00647: "NKTR-171: Preclinical Efficacy and Improved Central Nervous System (CNS) Side Effect Profile of a Novel Sodium Channel Blocker Designed for the Treatment of Neuropathic Pain", Gursahani, H., et al. 
  • Date: May 25, 2013, 1:30 p.m. – 3:30 p.m. Eastern Time
  • Poster Session II
  • College on Problems of Drug Dependence 75th Annual Meeting, San Diego, CA:

  • Poster 1598130: "Opioids With Lower Brain Uptake Are Less Recognizable in Rat Drug Discrimination Tests and thus Potentially Less Subject to Abuse", Harrison, S., et al. 
  • Date: June 19, 2013, 12:00 p.m. – 2:00 p.m. Pacific Time
  • Poster 1605508: "Abuse Potential Assessment of Novel Opioid Analgesic NKTR-181: Implications for Labeling", Webster, L., et al. 
  • Date: June 20, 2013, 7:30 a.m. – 9:30 a.m. Pacific Time
  • Conference Call to Discuss Fourth Quarter and Year-End 2012 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time today, Thursday, February 28, 2013.

    This press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Friday, March 15, 2013.

    To access the conference call, follow these instructions:

    Dial: (877) 881.2183 (U.S.); (970) 315.0453 (international)
    Passcode: 98224860 (Nektar Therapeutics is the
    '/>"/>

    SOURCE Nektar Therapeutics
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
    2. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
    3. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
    4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City
    5. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012
    6. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
    7. Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain
    8. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
    9. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
    10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
    11. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... ResMed (NYSE: RMD ) has introduced ... the United States . The Astral platform ... life support ventilators. ResMed,s new Astral ... use for patients suffering from neuromuscular disease, chronic obstructive ... disorders. The U.S. launch comes on the heels of ...
    (Date:9/2/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Administration (FDA) has granted orphan drug status to APD811 ... "The FDA Office of Orphan Products Development (OOPD) ... identify and designate drug candidates that could potentially treat ... of such products," said Craig M. Audet , ...
    (Date:9/2/2014)... 2014   Intrexon Corporation (NYSE: ... that it has entered into an Exclusive Channel Collaboration ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... family of its marketed Active Pharmaceutical Ingredients (APIs) through ... . This collaboration will leverage Intrexon,s proprietary technology suite ...
    Breaking Medicine Technology:ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
    (Date:9/2/2014)... Humility of Mary Health Partners will offer a ... Health Center, 1044 Belmont Ave. , The workshop includes an ... common health problems as well as tips on caring for ... on when to seek medical attention. , The morning ... Room; the evening session runs from 5:30 to 6:30 p.m. ...
    (Date:9/2/2014)... 02, 2014 A little bit of ... sometimes the onset of irritability, sadness, or apathy can ... September 2014 Harvard Health Letter. , "Mood-related ... stresses. If they occur for long periods, cause significant ... to seek help," says Dr. Nancy Donovan, an instructor ...
    (Date:9/2/2014)... Eric Jimenez and Leah Ashley announced ... revolutionary makeup application device. Designed to improve and accelerate ... the palm of women’s hands to help them get ... Me’s success lies in its patented technology. With a ... 15,000 pulses per minute, the device applies foundation evenly ...
    (Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
    (Date:9/2/2014)... Syracuse, NY (PRWEB) September 02, 2014 ... A. Gadlage, M.D. & Associates in Duluth, GA and ... the EarQ team at the 2014 National ... in Cancun, Mexico. , While interacting with the former ... maintaining hearing health, the team provided free hearing screenings, ...
    Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:The EarQ Team Brings Hearing Health Awareness to the 2014 National Basketball Retired Players Association Annual Convention in Cancun 2
    ... a few glasses of wine enough to disrupt normal development, ... Just a few glasses of wine over a short period ... the Medical College of Georgia. , The initial signs ... include facial malformations such as a flat and high upper ...
    ... Benefit Muscular Dystrophy Research , ... Iselin, NJ (PRWEB) ... [Sanford-Brown Iselin] (SBI), in New Jersey, raised $11,000 for muscular ... the event are in support of local non-profit www.ryansquest.org ...
    ... to recent news,about Michigan,s first identified case of chronic ... issued the following statement., With hunting season fast ... a deer on a Kent County farm understandably has,created ... great state of Michigan. The deer farming industry in ...
    ... Surgery Seems to be the Provider of Choice for Recent,Big ... Next?, Months of constant cameras, mirrors all around and ... a major impact on how you feel,about the way you ... reality. Upon leaving the house contestants may undoubtedly spend,hours watching ...
    ... to $19 million, NATICK, Mass., Aug. 29 ... the U.S. District Court of,Marshall, Texas found two patents ... conduct during the prosecution of the patents,before the United ... previously found that certain Boston Scientific balloon,catheters and stent ...
    ... leadership and State delegations as a possible solution to national health ... ... 2008 -- If there has been any one consistent message offered ... the party platform initiative to resolve our national health care issues., ...
    Cached Medicine News:Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Deer Farm Industry in Michigan Issues Statement on the Recent Chronic Wasting Disease Case Identified on a Kent County Deer Farm 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2
    ...
    The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
    The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
    The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
    Medicine Products: